SCHEMBL16185123

SCHEMBL16185123

CNc1nc(-c2ccccn2)nc2c(OC)cc(-c3ccccc3F)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ CYP1A2 P05177 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ CYP2D6 P10635 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ CYP2C19 P33261 2/20 0.46
▸ TDP1 Q9NUW8 2/20 0.46
▸ TSHR P16473 1/20 0.46
▸ ABCB1 P08183 2/20 0.43
▸ ABCG2 Q9UNQ0 2/20 0.43
▸ METAP2 P50579 1/20 0.41
▸ METAP1 P53582 1/20 0.41
▸ TRPM8 Q7Z2W7 5/20 0.41
▸ MAPT P10636 4/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MITF O75030 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474674 0.93 SMN1; SMN2 (0.43) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL14474671 0.91 L3MBTL1 (0.47) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL16185151 0.91 L3MBTL1 (0.45) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL16185124 0.91 CYP1A2 (0.46) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL14475260 0.90 GRM5 (0.42) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL16184182 0.89 CYP1A2 (0.41) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL14475254 0.89 CYP1A2 (0.43) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL16185122 0.88 ALDH1A1 (0.42) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL14474182 0.88 ABCB1 (0.47) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10
SCHEMBL14474188 0.88 ABCB1 (0.47) LMNASMN1; SMN2KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB LMNA 4832/4885SMN1; SMN2 3987/4885KDM4E 1395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback